An Interest In:
Web News this Week
- March 28, 2024
- March 27, 2024
- March 26, 2024
- March 25, 2024
- March 24, 2024
- March 23, 2024
- March 22, 2024
Some of Our Sources
- Techcrunch
- Simplebits
- TutsPlus - Code
- Web Designer Wall
- Team Treehouse
- Six Revisions
- Inspiredology
- Web Resource Source
- Daily Now
- The Verge
Help Webnuz
Referal links:
February 25, 2013 06:11 pm GMT
In August 2011, Intersect won approval from the FDA for Propel, which, simply put, is a stent that doctors implant in the sinuses after surgery to help keep them open. The cool part is that, over time, the stent absorbs into the patient's body post-surgery (so that follow-up surgery isn't required), slowly releasing a steroid to help control local inflammation, according to Medgadget. In the fall of last year, the company won approval again for the Propel Mini, a miniaturized version of its flagship product designed for "less extensive surgeries," Medgadget says.
Original Link: http://feedproxy.google.com/~r/Techcrunch/~3/MOWvOOQwBkY/
Intersect ENT Lands $30M From Norwest, Kleiner, USVP & More For Its Innovative Sinus Drug & Device Combo
In August 2011, Intersect won approval from the FDA for Propel, which, simply put, is a stent that doctors implant in the sinuses after surgery to help keep them open. The cool part is that, over time, the stent absorbs into the patient's body post-surgery (so that follow-up surgery isn't required), slowly releasing a steroid to help control local inflammation, according to Medgadget. In the fall of last year, the company won approval again for the Propel Mini, a miniaturized version of its flagship product designed for "less extensive surgeries," Medgadget says.Original Link: http://feedproxy.google.com/~r/Techcrunch/~3/MOWvOOQwBkY/
Share this article:
Tweet
View Full Article
Techcrunch
TechCrunch is a leading technology blog, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.More About this Source Visit Techcrunch